{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:18:10Z","timestamp":1790806690635,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000654","name":"Mount Vernon Marie Curie Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clon.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T09:08:56Z","timestamp":1573117736000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"P.","family":"Chitmanee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tharmalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Alonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ostler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clon.2019.10.008_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.23161","article-title":"Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes","volume":"112","author":"Agarwal","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0360-3016(03)00784-3","article-title":"Radical prostatectomy, external beam radiotherapy; 72 Gy, external beam radiotherapy;72 Gy, permanent seed implantation, or combined seeds\/external beam radiotherapy for stage T1 and T2 prostate cancer","volume":"58","author":"Kupelian","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2019.10.008_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2014.09.017","article-title":"Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer specific mortality by nomogram-predicted risks of biochemical recurrence","volume":"67","author":"Lee","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2015.10.021","article-title":"A\u00a0Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study","volume":"118","author":"Kaljouw","year":"2016","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.clon.2019.10.008_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clon.2019.10.008_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.brachy.2017.07.013","article-title":"Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time","volume":"16","author":"Kollmeier","year":"2017","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.clon.2019.10.008_bib8","first-page":"762","article-title":"Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer","volume":"188","author":"Barzell","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2019.10.008_bib10","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2011.04.031","article-title":"High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence","volume":"82","author":"Hoskin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2019.10.008_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2011.07.009","article-title":"PSA nadir of <0.5 ng\/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure","volume":"83","author":"Ko","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13014-017-0884-y","article-title":"Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation","volume":"12","author":"Geara","year":"2017","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2019.10.008_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2016.5983","article-title":"Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: a secondary analysis of a randomized clinical trial","volume":"3","author":"Royce","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.clon.2019.10.008_bib14","article-title":"Association of nadir prostate-specific antigen >0.5 ng\/mL after dose-escalated external beam radiation with prostate cancer-specific endpoints","volume":"10","author":"Sheth","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.clon.2019.10.008_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00066-017-1157-2","article-title":"High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy","volume":"193","author":"Chatzikonstantinou","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2019.10.008_bib16","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.brachy.2016.04.301","article-title":"Single fraction HDR brachytherapy as monotherapy in patients with prostate cancer: what is the optimal dose level?","volume":"15","author":"Roos","year":"2016","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.clon.2019.10.008_bib17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clon.2019.10.008_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5114\/jcb.2016.61067","article-title":"Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer","volume":"8","author":"Zamboglou","year":"2016","journal-title":"J\u00a0Contemp Brachyther"},{"issue":"2","key":"10.1016\/j.clon.2019.10.008_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0167-8140(96)01770-7","article-title":"Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate","volume":"40","author":"Zietman","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2019.10.008_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1748-717X-8-170","article-title":"A\u00a0prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy","volume":"8","author":"Jackson","year":"2013","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2019.10.008_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1748-717X-9-102","article-title":"Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity","volume":"9","author":"Henr\u00edquez","year":"2014","journal-title":"Radiat Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:47:34Z","timestamp":1760543254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655519304571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0936655519304571"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2019.10.008","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}